Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia
Eleni Tholouli, Effie Liakopoulou, Hayley M. Greenfield, Bronwen E. Shaw, Sudhir Tauro, Jennifer L. Byrne, Mike Dennis, John Burthem, Guy S. Lucas, Charles Craddock, Nigel H. Russell, John A. Liu YinVolume:
142
Année:
2008
Langue:
english
Pages:
3
DOI:
10.1111/j.1365-2141.2008.07184.x
Fichier:
PDF, 126 KB
english, 2008